Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14169495 | 0.83 | — | — | |
| SCHEMBL24730516 | 0.82 | L3MBTL1 (0.45) | L3MBTL1CHRM3 | |
| SCHEMBL14268232 | 0.82 | L3MBTL1 (0.45) | L3MBTL1CHRM3 | |
| SCHEMBL23206200 | 0.80 | HDAC8 (0.43) | — | |
| SCHEMBL24712789 | 0.79 | S1PR1 (0.36) | L3MBTL1 | |
| SCHEMBL26512146 | 0.78 | SPHK2 (0.34) | L3MBTL1CHRM3 | |
| SCHEMBL22063588 | 0.78 | CHRM3 (0.34) | L3MBTL1CHRM3 | |
| SCHEMBL26512063 | 0.78 | DRD2 (0.37) | — | |
| SCHEMBL23023335 | 0.77 | GBA1 (0.36) | — | |
| SCHEMBL24731188 | 0.77 | CRHR1 (0.30) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2021031952-A1 | OXYGEN-SUBSTITUTED SIX-MEMBERED RING PYRIMIDINE COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | L3MBTL1 2625/4885CHRM3 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.